Grifols, S.A. (NASDAQ:GRFS - Get Free Report) shares saw an uptick in trading volume on Thursday . 1,622,142 shares traded hands during mid-day trading, an increase of 102% from the previous session's volume of 804,488 shares.The stock last traded at $8.41 and had previously closed at $7.94.
Analyst Ratings Changes
Separately, Morgan Stanley initiated coverage on shares of Grifols in a research note on Wednesday, February 12th. They set an "overweight" rating for the company.
Get Our Latest Research Report on GRFS
Grifols Stock Up 1.7 %
The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The firm has a 50 day simple moving average of $7.42 and a two-hundred day simple moving average of $8.13. The company has a market capitalization of $5.90 billion, a PE ratio of 7.33 and a beta of 0.40.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in GRFS. GAMMA Investing LLC raised its stake in shares of Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after buying an additional 1,527 shares in the last quarter. HighTower Advisors LLC raised its position in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock worth $123,000 after acquiring an additional 1,546 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Grifols by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after acquiring an additional 1,657 shares during the period. US Bancorp DE lifted its holdings in Grifols by 12.3% in the third quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company's stock valued at $183,000 after acquiring an additional 2,256 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Grifols by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company's stock worth $192,000 after purchasing an additional 2,403 shares in the last quarter.
About Grifols
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Further Reading
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
